During SEUD,
Presentation details are as follows:
Title: Recovery of Bone Mineral Density (BMD) after Long Term Treatment with Linzagolix in Women with Endometriosis: Results from a Phase 2b Dose-Ranging Trial
- Format: Oral Presentation
- Presenter: Jacques Donnez
- Session Date & Time:
Free Communications 1 beginningFriday, December 10 th at4:30 p.m. CET
Title: Long Term Efficacy of Linzagolix for Treatment of Heavy Menstrual Bleeding (HMB) due to Uterine Fibroids (UF): 52-Week Results from Two Placebo-Controlled, Randomized, Phase 3 Trials
- Format: Oral Presentation
- Presenter:
Hugh Taylor - Session Date & Time:
Free Communications 6 beginningFriday, December 10 th at5:30 p.m. CET
Title: Long Term Safety and Tolerability of Linzagolix for Treatment of Heavy Menstrual Bleeding (HMB) due to Uterine Fibroids (UF): 52-Week Results from Two Placebo-Controlled, Randomized, Phase 3 Trials
- Format: Oral Presentation
- Presenter: Jacques Donnez
- Session Date & Time:
Free Communications 6 beginningFriday, December 10 th at5:30 p.m. CET
About
Cautionary Note Regarding Forward Looking Statements of
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Obseva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development and potential therapeutic and clinical benefits of and commercialization plans for Obseva’s product candidates, including linzagolix, expectations regarding regulatory and development milestones, including the potential timing of and Obseva’s ability to obtain and maintain regulatory approvals for its product candidates, and the results of interactions with regulatory authorities, including the FDA and EMA. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include that FDA’s review of the linzagolix NDA may determine that the existing clinical data is insufficient to support approval or that significant labeling limitations would be required, uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, Obseva’s reliance on third parties over which it may not always have full control, and the capabilities of such third parties; the impact of the ongoing novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of Obseva’s Annual Report on Form 20-F for the year ended
For further information, please contact:
CEO Office contact
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
jallaire@lifesciadvisors.com
+1 (617) 435-6602
Attachment
- Press Release in Pdf
Source:
2021 GlobeNewswire, Inc., source